L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
Nanoker Research S.L. is a Spanish developer and manufacturer of advanced technical and nanocomposite ceramic products & solutions for diverse top-end applications through mastering of material science and cutting-edge industrial processing methods.
Oviedo, Asturias, Spain
Send a message
Nanoker has just joined a community of 100+ European Tech companies willing to consider the financial markets as part of their financing strategy, through the TechShare Program by EURONEXT.
We applied in October and are thrilled to have been selected for the 6th edition of the program. For us, it’s an exciting and important step towards raising the necessary funding for our ground-breaking tech solutions based on Material Science.
TechShare is the pre-IPO educational training programme by EURONEXT. It helps Tech entrepreneurs to familiarise themselves with capital markets.
With the support of 75 partners from the financial industry, TechShare has trained more than 400 Tech companies since the launch of the programme.
TechShare is currently available in Belgium, France, Germany, Italy, the Netherlands, Portugal, Spain and Switzerland. It is also a networking enabler, connecting Tech entrepreneurs and capital markets advisors throughout the year.
Selected for their great innovation capacity, participants in TechShare are growing businesses that are active in the Tech industry, which have significant funding needs for their projects and growth, and are likely to consider Capital Markets as an option to raise equity within 2-3 years.
TechShare provides three different modules of knowledge sharing: academic campuses, workshop sessions and individual coaching. The content is provided by committed partners from the financial industry: investment bankers, auditors, lawyers, financial communication and investor relations experts.
From January 2021 to June 2021, Nanoker, with the rest of participants will attend European events, local group sessions but also one-to-one trainings to benefit from customised advice.
Specifically, twice a year, in January and June, academic seminars are organised with prestigious European business schools to encourage networking between partners and participants, as well as interaction through breakout sessions, plenary keynotes and discussions with entrepreneurs.
Interactive courses are held on a regular basis locally by the partners to educate the participants on capital markets. Topics include: why to go public, the IPO process, the legal perspective, the valuation strategy, financial communication, how to attract investors and life as public company.
Throughout the year, all participants receive individual training and tailor-made mentoring with dedicated professionals: auditors, lawyers, financial communication experts. These one – to- one coaching meetings with partners are a unique opportunity for companies to discuss their main challenges.
EURONEXT is the European capital raising centre. It supports companies from local and international blue chips to small and medium enterprises with listing services to meet their specific needs. Issuers in all geographies and from all sectors can grow by raising capital on the regulated markets in Amsterdam, Brussels, Dublin, Lisbon, London and Paris, and benefit from exposure to the exchange’s diverse, international client base.
Euronext is also the largest listing venue for Tech companies in Europe with 479 Tech issuers. In order to facilitate the access to capital markets of fast-growing SMEs, Euronext Growth, labelled SME Growth Market.
SME Growth Market is a tailor-made market compartment with asset managers and retail investors providing liquidity to small and midcaps. With 212 new Tech listings since 2013, Euronext is the most dynamic market in Europe for Tech companies. Euronext also offers the most diverse and international investor base, having more than 1,600 institutional investors in the Tech sector, of which one third is from the US.
2021 has started with fresh corporate news & moves rocking the ceramic dental implant world. And this is good for a few reasons.
The swiss manufacturer Dentalpoint AG has, since 2009 developed and improved its ZERAMEX® ceramic implant system. ZERAMEX® is one of the (few) alternatives for a full ceramic solution. It features a traditional ceramic material (ATZ) and a 2 piece screwed/threaded (not screw-retained) design. Abutment is threaded to the implant base, and crown is cemented to the abutment. The system is nevertheless enhanced in its base osseointegration performance thanks to an hydrophilic surface treatment, which is then sandblasted to achieve osteoblasts growing directly up to the implant.
Other characteristic feature of this evolving full ceramic system is the reinforced strength of the base-abutment connection, which is made of an intermediate carbon fiber threaded-interface. This improves to a certain extent the mechanical performance of the ATZ and eases the screwing of the abutment piece. Additional retentive elements in the form of a “Bolt-In-Tube” connection were added in the newest XT version.
Abutments are manufactured in Hot Isostatic Pressed (HIP) ATZ. Additionally, the carbon fiber intermediate thread helps better sealing and isolating the connection against bacterial growth.
The minimum diameter achieved for the ZERAMEX® family of implants is 3,5mm, something remarkable for a ceramic base, and although the two pieces make up for a monolitic form, abutments allow crown tilting of up to 15 degrees.
As for its market strategy, in its website, Dentalpoint states that, [quote] “In December 2017, Nobel Biocare entered the ceramic implant market and entered into a partnership with Dentalpoint. Under its own brand, Nobel Biocare distributes the ceramic implant worldwide and exclusively“.
But Dentalpoint was not only producing exclusive “white label” for Nobel Biocare. Its business model called for the use of its own brand through distributors (globally) and through its own, growing salesforce. Also, direct sales to premium clinics and dentist in Switzerland, Austria, and… GERMANY.
As from the Dentalpoint AG website, this is the market strategy and distribution approach that is envisaged for their all ceramic dental implant portfolio.
CERAMTEC AND ITS MOVE
Meanwhile, in Germany, CERAMTEC Group, a technical ceramics champion with a strong protesic division that includes a dental implant line (rather secondary vs. their BIOLOX® which is mainly hip replacement oriented), was trying to promote its own two piece screwed ceramic implant system: DENSILOX®. Although quite similar to ZERAMEX®, it shows different features and a somehow simpler design. For instance, the system offers the choice in materials between ATZ, Y-TPZ and ZTA. However, minimum implant base diameters are in excess of 4mm.
Now, CERAMTEC just acquired Dentalpoint AG. This is a major development in the industry. See all details in the release by Ceramtec.
Both companies seem happy with the deal [Quote from the release]:
Of course, Ceramtec now controls a competitor that was most probably eroding its market share (in Germany and elsewhere).
“With this acquisition, we not only consistently expand our portfolio in the Medical segment, but at the same time we are expanding our access to the dental market, our product development expertise and our manufacturing capacities in a strongly growing market environment” says Dr. Hadi Saleh, CEO of the CeramTec Group.
And Dentalpoint cashes on their technology and technical development, and on their multi-channel successful growth strategy, while seeing their brand and company survive -at least in the short term- the acquisition.
Adrian Hunn, CEO of Dentalpoint AG, adds: “Through the integration into the CeramTec Group, we expect new impulses for our existing business and the expansion of our international presence. At the same time, Dentalpoint will remain a stand-alone company with the established Zeramex brand and will continue to expand.”
It is indeed quite remarkable that Dentalpoint AG is keeping its corporate identity as a Swiss subsidiary of Ceramtec, and that ZERAMEX® will remain a dental implant line brand. It’s not clear what will happen with Ceramtec’s own DENSILOX® one.
But, there is more than meets the eye in this corporate move.
THIS WAS NOT THE (expected) PLAN
Nobel Biocare is a leading implant Swiss company, specialised in Titanium based systems. It was acquired back in 2014 by US Danaher Corp., and is now part of the ENVISTA Group (spun-off from Danaher Holding in 2019), which is the world’s second biggest dental implant manufacturer and supplier, and one of the seven big groups that cope more than 80% of the global dental implant market. All these groups center their business around the titanium implant systems, and have managed to keep the entrance of ceramic solutions at bay. None of the 7 Groups is based in the EU, although this is the world’s biggest dental implant market (more than 40% global share).
For quite sometime, Nobel pursued the idea that Ceramtec would become their supplier for a two-piece ceramic implant and other ceramic medical devices. However, Ceramtec refused and decided to try and enter the market with their own brand and product line (DENSILOX®), leaving aside the idea of resorting to a distributor/competitor such as Nobel.
Nobel found an alternative in Dentalpoint AG and in the development of exclusive “white line” distribution of their ZERAMEX® system. This was, as we have seen, part of Dentalpoint sales channel strategy.
In fact, at the IDS (Internationale Dentalschau = International Dental Exhibition) in Köln in march 2019, the debut of Nobel’s new Ceramic Dental Implant (distributed, not indigenously produced) line was expected, but instead, it was Ceramtec that presented their own.
However, just a few months later, at the 1st European Congress for Ceramic Implant Dentistry organised by ESCI in Zurich beginning of october 2019, before over 170 participants from 23 countries, Nobel presented ZERAMEX® as their choice for DISTRIBUTION of an all-Ceramic 2 piece Implant. Probably Ceramtec reflected on that, since this considerably endorsed and reinforced its ceramic rival Dentalpoint, and was theoretically detrimental to Ceramtec’s line DENSILOX®.
At that moment (little more than a year ago), and to summarize: There was Ceramtec on their propietary DENSILOX®, Nobel Biocare with their exclusive distribution of ZERAMEX®, and Dentalpoint AG with direct sale and distribution under their brand of the same ZERAMEX®. Let’s remember that we’re talking about two very similar implant systems.
WHAT LAYS AHEAD
With its acquisition of Dentalpoint AG, Ceramtec clearly consolidates the all ceramic 2 piece threaded implant offer. But most importantly, it bets on consolidating and expanding of the development, manufacturing, branding and DIRECT SALES of the ceramic implant alternative vs. resorting to “white label” distribution through titanium big players. The latter would mean helping them completing their portfolio and improving their image by offering a ceramic alternative, in front of the increased public awareness about titanium associated problems in dental implantology.
Regardless of the continuity of the distribution agreement between Dentalpoint and Nobel, it now remains to be seen if shockwaves will trigger any reaction (in the form of corporate moves, integration, or acceleration in the development of their own ceramic solutions) from the big titanium players that dominate the market, or if, either alternatively or simultaneously further defensive or strengthening consolidation in the still small ceramic realm will be seen.
We’ll be watching and keep you updated, as we, at Nanoker, are finalising the CE/MDR marking of our own disruptive and much superior Monoblock patented nanocomposite material and unique design of they INPERIO system.
Start in 2011
Nanoker Research S.L. is incorporated, founded by Prof. Torrecillas and industrial partners.
to be continued ...